Corbus Pharmaceuticals reported topline data from the CANYON-1 trial of oral CRB-913. We review the 12-week weight loss results, insomnia rates, and safety data.
On September 14, 2026, Corbus Pharmaceuticals announced positive topline results from CANYON-1. The Phase 1b trial evaluated once-daily oral CRB-913 in 254 adults with obesity who did not have diabetes. The study used a 16-week, double-blind, placebo-controlled, dose-ranging design across 15 sites in the United States.
This data provides an early look at a potential new class of weight-management medications. The findings highlight preliminary efficacy and specific tolerability observations. For patients and clinicians weighing pharmacologic options, understanding the potential side effects is critical. Safety monitoring remains a central part of any responsible treatment plan.
CRB-913 is being developed as a potential oral, non-incretin obesity medicine. This could make it relevant for patients seeking new appetite control options outside of incretin-based treatments. Corbus describes the drug as a highly peripherally restricted CB1 inverse agonist. The cannabinoid receptor system plays a large role in regulating metabolism and energy balance throughout the body.
Historically, blocking these receptors in the brain caused severe psychiatric side effects. A peripherally restricted medication targets receptors in the body while minimizing penetration into the central nervous system. Company CEO Yuval Cohen noted the study was intended to test this specific peripheral approach. The goal is to provide a tolerable alternative to oral GLP-1 medicines while producing competitive weight loss.
Early in our research, we reviewed a study showing how just a few nights of poor sleep could significantly alter appetite hormones. It was a clear revelation. So many people were meticulously tracking their food but completely ignoring their sleep and stress levels. We immediately shifted our editorial focus to include recovery as a fundamental pillar of weight management alongside nutrition and movement.
The medical community is eager for new treatment pathways, but headlines often rush to conclusions. The reported least-squares mean weight reduction of 5.0% at the 60 mg dose sounds promising to many observers. However, these are topline results from a short 12-week active treatment period with four weeks of follow-up. That duration is insufficient to determine long-term weight maintenance or chronic side effects.
Corbus published comparisons with liraglutide, semaglutide, and tirzepatide in its safety table. The company explicitly characterized those numbers as cross-trial comparisons rather than head-to-head evidence. The comparator studies were also much longer, running from 36 weeks up to 72 weeks. Comparing adverse-event percentages across studies with different durations and populations can be highly misleading.
The trial used a 1:1:1:1 randomization scheme for participant assignment. There were 66 participants in the placebo group, 65 in the 20 mg group, 61 in the 40 mg group, and 62 in the 60 mg group. At week 12, the least-squares mean weight change from baseline was 0.0% with placebo. The active groups showed reductions of 2.8% with 20 mg, 3.3% with 40 mg, and 5.0% with 60 mg.
The company reported p-values below 0.0001 for each active dose versus placebo. Among participants who completed the study and received the 60 mg dose, 44.4% lost at least 5.0% of baseline body weight. In that same group, 6.7% lost more than 7.5%, and the greatest recorded weight loss was 13.4%. Harold Bays, an investigator in CANYON-1, emphasized the apparent lack of a weight-loss plateau during the 12-week treatment period.
Psychiatric safety and sleep tolerability are critical areas of focus for this drug class. There were no serious or severe psychiatric adverse events among the 188 participants who received CRB-913. The company also reported no cases of suicidality during the trial. One participant experienced transient moderate depressive symptoms.
A comprehensive psychiatric safety review involves looking at all reported mood and sleep changes. Irritability was the most common psychiatric adverse event reported by the company. It occurred in 6.2% of the 20 mg group, 8.2% of the 40 mg group, and 9.7% of the 60 mg group. All reported cases of irritability were classified as mild.
The reported insomnia rates were 3.0% with placebo, 1.5% with CRB-913 at 20 mg, 4.9% at 40 mg, and 0% at 60 mg. These percentages come from relatively small dose cohorts. A difference of only a few participants can materially change the final percentage in a group of this size. The absence of a clear dose response does not definitively prove the medication has no effect on sleep.
Gastrointestinal adverse events were described as mild or moderate in the trial data. There were no serious or severe gastrointestinal cases reported. Reported nausea rates were 15.4% at 20 mg, 26.2% at 40 mg, and 22.6% at 60 mg. Corbus reported treatment discontinuation because of adverse events in 3.1% to 13.1% of CRB-913-treated participants.
Vomiting occurred in 4.6%, 8.2%, and 1.6% of those groups, respectively. Constipation occurred in 4.6%, 1.6%, and 4.8% across the same active cohorts. These tolerability metrics are important for understanding day-to-day patient experiences. Efficacy must always be balanced against a realistic assessment of physical comfort and daily functioning.
For patients and clinicians, the most defensible takeaway is that sleep should be closely monitored. CANYON-1 reported insomnia in some participants, but the dose-level percentages did not show a consistent increase. The publicly reported results lack detailed information about baseline sleep quality, pre-existing insomnia, or sleep apnea. They also omit data regarding work schedules or use of sleep medications that could affect reporting.
A practical monitoring approach could include recording baseline sleep quality and tracking daily energy levels. Patients might note changes in sleep onset, nighttime awakenings, early-morning waking, and daytime fatigue. Persistent changes should always be discussed with a prescribing clinician. Anyone struggling with chronic rest issues might consider behavioral treatment for insomnia as a supplementary habit.
Patients should avoid interpreting a single poor night as proof of a medication effect. Sleep can be heavily influenced by stress, caffeine, and daily work schedules. The public CANYON-1 report does not provide enough detail to separate those complex environmental factors. Anyone experiencing sleep disruption alongside severe anxiety or mood changes should contact their doctor before stopping medication.
The study was conducted in adults with obesity who did not have diabetes. Because of this specific criteria, the findings may not generalize to people with diabetes. They also may not apply to older adults, people with significant sleep disorders, or patients taking multiple medications. Harold Bays positioned CRB-913 as a possible option for patients who do not tolerate GLP-1 medicines.
He suggested it might help those who do not achieve an adequate response from incretin therapies. His comments should be presented as an investigator perspective rather than an established treatment recommendation. At WeightRestart, we believe in treating a complex biological system with care. Any new medication must prove it supports healthy habits and daily physical functioning.
Corbus plans to discuss the CANYON-1 data in a late-breaking presentation at ObesityWeek 2026. This medical conference is scheduled for November 14 to 17, 2026. The company said it plans to engage with the U.S. Food and Drug Administration regarding its clinical development plan. They expect to begin a Phase 2 monotherapy study in the first half of 2027.
Corbus is also evaluating whether CRB-913 could be combined with GLP-1 therapy. Future research is needed to determine true long-term weight maintenance and chronic side effect profiles. The limited 12-week treatment duration prevents any firm conclusions about sustained metabolic improvements. We must await larger studies before this approach can be considered a standard medical practice.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
